Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN V HEYMACH

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1417056565
CMS profile
245762
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$160,752.57

111 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN V HEYMACH

NPI 1417056565 · CMS profile ID 245762

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1417056565?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN V HEYMACH, NPI 1417056565, CMS profile ID 245762. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417056565?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JOHN V HEYMACH, NPI 1417056565, CMS profile ID 245762. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417056565?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JOHN V HEYMACH, NPI 1417056565, CMS profile ID 245762, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–111 of 111 matching records. This page contains 11 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1417056565?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

111 matching records · $160,752.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 111 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–111 of 111.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $81.3501/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078725981 CMS
Janssen Biotech, Inc. $173.3501/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078722529 CMS
Janssen Biotech, Inc. $63.8701/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078724640 CMS
Janssen Biotech, Inc. $181.3501/18/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078730323 CMS
BioNTech SE $3,603.2001/16/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150660510 CMS
Janssen Biotech, Inc. $816.4301/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078724944 CMS
Janssen Biotech, Inc. $700.0001/12/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078730094 CMS
Boehringer Ingelheim International GmbH $217.2401/11/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117999397 CMS
Boehringer Ingelheim International GmbH $461.7701/11/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117999407 CMS
Boehringer Ingelheim International GmbH $505.5501/11/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117999411 CMS
Boehringer Ingelheim International GmbH $556.1001/11/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117999417 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $97,291.84 112
PY2020 $114,753.07 136
PY2021 $74,784.33 44
PY2022 $86,966.53 63
PY2023 $65,857.75 69
PY2024 $160,752.57 111
PY2025 $125,712.41 77

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,205,094.68 86
PY2024 Principal investigator $1,248,647.12 9
PY2023 Recipient $543.79 1
PY2023 Principal investigator $1,866,391.56 16
PY2022 Principal investigator $1,123,526.96 7
PY2021 Recipient $1,386.68 2
PY2021 Principal investigator $783,527.48 7
PY2020 Principal investigator $1,097,038.73 8
PY2019 Principal investigator $1,829,138.77 8

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

86 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $298,840.32 12/25/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220810122
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 12/01/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577944
Principal investigator 1 Boehringer Ingelheim Espana S.A. $19.98 12/01/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577946
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $368,373.84 11/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997704
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,666.19 11/13/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220810120
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,588.89 11/12/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220810116
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,144.99 11/12/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220810118
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 11/01/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577940
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 11/01/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577942
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $276,280.38 10/31/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997700
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $621.85 10/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220810114
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $146.50 10/27/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997706
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $99.90 10/27/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997708
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $888.25 10/23/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220810112
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 10/01/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577938
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $378,606.44 09/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997702
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $561.19 09/25/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220810110
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $703.20 09/24/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997690
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $174.90 09/24/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997692
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $179.82 09/24/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997694
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3.60 09/24/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997696
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $931.50 09/23/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220810108
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $602.38 09/11/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220810104
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $752.00 09/11/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220810106
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $901.81 09/05/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220810102
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $91,136.51 09/04/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220810100
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 09/01/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577936
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $378,606.44 08/31/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997698
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $996.20 08/26/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997682
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $303.16 08/26/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997684
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $519.48 08/26/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997686
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $15.60 08/26/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997688
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $907.31 08/21/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220810098
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $968.04 08/20/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220810088
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $363.64 08/20/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220810090
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,367.98 08/20/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220810092
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $897.60 08/20/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220810094
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $975.61 08/20/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220810096
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,176.44 08/12/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220810086
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 08/01/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577934
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $439.50 07/28/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997676
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $299.70 07/28/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997678
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $12.00 07/28/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997680
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,109.12 07/28/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220810084
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $650.00 07/25/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220810082
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $846.26 07/18/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220810080
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $599.17 07/10/2025 Covered Recipient Teaching Hospital
Mayo Clinic Hospital
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220793969
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,311.23 07/10/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220810078
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 07/01/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577964
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,640.61 07/01/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220810072
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $846.53 07/01/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220810074
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $17,625.00 07/01/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220810076
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $895.16 06/16/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220810070
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 06/01/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577962
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $42.41 06/01/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase Ia/Ib, open-label, multicentre dose-escalation and expansion study to investigate the safety, pharmacokinetics and preliminary efficacy of BI 1823911 as a monotherapy and in combination with other anti-cancer therapies in patients with advanced or metastatic solid tumours expressing KRAS G12C mutation No dispute reported 06/30/2026 1220997652
Principal investigator 1 AstraZeneca Pharmaceuticals LP $119,378.66 05/30/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients with Non-Small Cell Lung Cancer, who Progressed on an anti-PD-1 PD-L1 Containing Therapy HUDSON No dispute reported 06/30/2026 1185549751
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $47.75 05/27/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997674
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 05/01/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577960
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $42.41 05/01/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase Ia/Ib, open-label, multicentre dose-escalation and expansion study to investigate the safety, pharmacokinetics and preliminary efficacy of BI 1823911 as a monotherapy and in combination with other anti-cancer therapies in patients with advanced or metastatic solid tumours expressing KRAS G12C mutation No dispute reported 06/30/2026 1220997650
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $317,437.80 04/18/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS, MD ANDERSON CANCER CTR
IST CCR-MDACC2-ALIS-001 (MDACC) DR. JOHNSON No dispute reported 06/30/2026 1251754236
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $126,727.89 04/14/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220810068
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 04/01/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577954
Principal investigator 1 Boehringer Ingelheim Espana S.A. $107.76 04/01/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577956
Principal investigator 1 Boehringer Ingelheim Espana S.A. $41.95 04/01/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577958
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $42.41 04/01/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase Ia/Ib, open-label, multicentre dose-escalation and expansion study to investigate the safety, pharmacokinetics and preliminary efficacy of BI 1823911 as a monotherapy and in combination with other anti-cancer therapies in patients with advanced or metastatic solid tumours expressing KRAS G12C mutation No dispute reported 06/30/2026 1220997648
Principal investigator 1 AstraZeneca UK Limited $135,000.00 03/27/2025 Non-covered Recipient Entity
UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
Evaluation of PRMT5 inhibitors and their activity in combination with immunotherapy in CDKN2A MTAP deficient preclinical models of NSCLC No dispute reported 06/30/2026 1185549755
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $673.90 03/25/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997668
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $459.54 03/25/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997670
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $8.40 03/25/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997672
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 03/01/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577952
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $42.41 03/01/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase Ia/Ib, open-label, multicentre dose-escalation and expansion study to investigate the safety, pharmacokinetics and preliminary efficacy of BI 1823911 as a monotherapy and in combination with other anti-cancer therapies in patients with advanced or metastatic solid tumours expressing KRAS G12C mutation No dispute reported 06/30/2026 1220997646
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $468.80 02/25/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997662
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $319.68 02/25/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997664
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $12.00 02/25/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997666
Principal investigator 1 AstraZeneca Pharmaceuticals LP $380,624.91 02/13/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
a phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non small cell lung cancer patients with non squamous histology who have mutations and or co mutations in skt11,keap1,or kras triton No dispute reported 06/30/2026 1185549753
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,864.12 02/09/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220810064
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 02/01/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577950
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $42.41 02/01/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase Ia/Ib, open-label, multicentre dose-escalation and expansion study to investigate the safety, pharmacokinetics and preliminary efficacy of BI 1823911 as a monotherapy and in combination with other anti-cancer therapies in patients with advanced or metastatic solid tumours expressing KRAS G12C mutation No dispute reported 06/30/2026 1220997644
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,465.00 01/27/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997654
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $46.64 01/27/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997656
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $839.16 01/27/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997658
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $22.80 01/27/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220997660
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $340.84 01/24/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220810066
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $277,838.35 01/03/2025 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
MDACC ALLIANCE - THORACIC No dispute reported 06/30/2026 1223272949
Principal investigator 1 Boehringer Ingelheim Espana S.A. $39.85 01/01/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
Beamion LUNG-1: An open label, Phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations No dispute reported 06/30/2026 1220577948
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $42.41 01/01/2025 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase Ia/Ib, open-label, multicentre dose-escalation and expansion study to investigate the safety, pharmacokinetics and preliminary efficacy of BI 1823911 as a monotherapy and in combination with other anti-cancer therapies in patients with advanced or metastatic solid tumours expressing KRAS G12C mutation No dispute reported 06/30/2026 1220997642

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2020 Amount invested $0.00 1
PY2020 Value of interest $93.69 1
PY2019 Amount invested $0.00 1
PY2019 Value of interest $221.46 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

2 records · PY2019–2020

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2020 IGIP, LLC $0.00 $93.69 2020 royalty payment. Physician Covered Recipient No dispute reported 06/30/2026 733499549
PY2019 IGIP, LLC $0.00 $221.46 This amount is a 2% royalty payment for ownership in IGIP, LLC for 2019. Physician Covered Recipient No dispute reported 06/30/2026 637952805